Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT04001231 Withdrawn - Type 2 Diabetes Clinical Trials

Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

Start date: June 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector in male and female Chinese with type 2 diabetes.

NCT ID: NCT03553524 Withdrawn - Type 2 Diabetes Clinical Trials

Circadian High Intensity Interval Training Study

Start date: October 30, 2021
Phase: N/A
Study type: Interventional

High intensity interval training (HIIT) is a promising intervention for treatment and prevention of type 2 diabetes. In spite of the interplay between circadian rhythms and exercise, the time of day in which the most robust adaption to HIIT can be achieved is unknown. The main goal of the study is to compare the efficacy of morning and afternoon HIIT in lowering blood glucose values in participants with type 2 diabetes.

NCT ID: NCT02611596 Withdrawn - Type 2 Diabetes Clinical Trials

Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this investigation is to compare subjects at high risk for silent myocardial ischemia in the placebo group to subjects at high risk for silent myocardial ischemia in the ranolazine group to determine if ranolazine can be used as a treatment to decrease silent myocardial ischemia (SMI). Subjects at high risk for silent myocardial ischemia are defined in this protocol as diabetics with stable ischemic heart disease. This study will look at the impact ranolazine treatment has on biomarkers that have been shown to be highly associated with increased risk of morbidity and mortality in relation to SMI. If the hypothesis is correct, further studies can be conducted to determine if treatment with ranolazine has impact on long-term outcomes such as hospitalizations, myocardial infarction, congestive heart failure or sudden cardiac death.

NCT ID: NCT02493374 Withdrawn - Type 2 Diabetes Clinical Trials

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

Start date: May 2016
Phase:
Study type: Observational

This is a study of people with type 2 diabetes and high cholesterol between age 18 and 65. This study is trying to figure out if a partial bypass of the small intestine can reverse type 2 diabetes for people who require cholesterol lowering and who cannot tolerate the statin drugs.

NCT ID: NCT02472717 Withdrawn - Type 2 Diabetes Clinical Trials

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

PLAQUE
Start date: May 2015
Phase: Phase 2
Study type: Interventional

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.

NCT ID: NCT02456922 Withdrawn - Type 2 Diabetes Clinical Trials

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Start date: July 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the performance of the Harmony 1 Sensor in subjects age 2 - 75 years

NCT ID: NCT02444364 Withdrawn - Type 2 Diabetes Clinical Trials

Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus

Start date: May 2015
Phase: Early Phase 1
Study type: Interventional

Participants will be persons with Type 2 Diabetes who are likely to have increased risk of bone fractures. The investigators believe this medication will enhance bone turnover. The investigators will use DXA measurements to evaluate bone density before and after subjects take the medication.

NCT ID: NCT02347709 Withdrawn - Type 2 Diabetes Clinical Trials

Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds

Start date: December 2014
Phase:
Study type: Observational

The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers. The secondary purpose will be to determine whether the degree of epidermal nerve fiber loss, the clinical examination, nerve conduction studies or the molecular profile correlates with appearance of lower extremity ulcers in patients with diabetes.

NCT ID: NCT02293720 Withdrawn - Type 2 Diabetes Clinical Trials

An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System

OLE
Start date: April 2015
Phase: N/A
Study type: Interventional

A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from study #09-1 who are not treatment failures and have completed 12 months of the study.

NCT ID: NCT02288351 Withdrawn - Obesity Clinical Trials

Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass

Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate small intestinal remodeling and reprogramming of glucose metabolism in patients with Type 2 Diabetes Mellitus (T2DM) who undergo laparoscopic Roux-en-Y Gastric Bypass (RYGB). Our specific goal is to determine if the gene and protein expression levels of GLUT-1 are up regulated in the Roux limb and whether this is a major mechanism for the remission of T2DM following RYGB. The two aims of the study are: 1) to demonstrate that the basement membrane glucose transporter 1 (GLUT-1) is upregulated in the Roux limb following RYGB, and 2) to demonstrate that the upregulation of GLUT-1 is a major mechanism for the improvement in glycemic control observed in T2DM patients undergoing RYGB.